The opportunity isn't incremental patients, it's reimbursement arbitrage
But for the goal of supporting collagen synthesis and improving skin quality over time, it works through pathways that retinol doesn't touch, and without the barrier disruption that makes retinol difficult for some people to sustain
Its a foundational principle for handling most sensitive biological compounds
Designed for sensitive skin, it combines anti-inflammatory ingredients with skin barrier support for comprehensive management
The logic behind alternating goes like this: if semaglutide only targets GLP-1 receptors and the body has adapted to that stimulation, switching to tirzepatide introduces GIP receptor activation as a new variable
They approve if an item ensures efficacy, quality, and safety and reject if it doesnt